Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

ANTIСONVALSANTS IN THE THERAPY OF BIPOLAR AFFECTIVE DISORDER

A.V. Ushkalova1, E.A. Ushkalova2
1 Private psychiatric clinic «Dushevnoe zdorovje»
2 Department of General and Clinical Pharmacology PFUR

Резюме.The article is a review of the literature on the use of anticonvulsants in bipolar affective disorder. The spectrum of activity of drugs of this group, their effectiveness in coping manic and depressive phases, preventive therapy, tolerability and major side effects, safety for prolonged use, as well as during pregnancy are considered.

References: 
  • 1. Laursen T.M., Wahlbeck K., Hällgren J. et al. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. // PLoS One. – 2013. –Vol. 8, No. 6. – E67133.
  • 2. Pfennig A., Bschor T., Falkai P., Bauer M. The diagnosis and treatment of bipolar disor-der: recommendations from the currents guideline // Dtsch Arztebl Int. – 2013. – Vol. 110, No. 6. – P. 92–100.
  • 3. Dilsaver S.C. An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009 // J Affect Disord. – 2011. – Vol. 129, No. 1–3. – P. 79–83.
  • 4. Geoffrey P.A., Bellivier F., Henry C. Treatment of manic phases of bipolar disorder: critical synthesis of international guidelines // Encephale. – 2014. – Vol. 40, No. 4. – P. 330–337.
  • 5. Baldessarini R.J., Tondo L., Visioli C. First-episode types in bipolar disorder: predictive associations with later illness // Acta Psychiatr Scand. – 2014. – Vol. 129, No. 5. – P. 383–392.
  • 6. Koukopoulos A., Reginaldi D., Tondo L. et al. Course sequences in bipolar disorder: de-pressions preceding or folowing manias or hypomanias // J Affect Disord. – 2013. – Vol. 151. – P. 105–110.
  • 7. Vázquez G.H., Holtzman J.N., Lolich M. et al. Recurrence rates in bipolar disorder: Sys-tematic comparison of long-term prospective, naturalistic studies versus randomized controlled trials // Eur Neuropsychopharmacol. – 2015. – [Epub ahead of print].
  • 8. Shafarenko A.A., Mosolov S.N. Sovremennaya terapiya maniakal'nykh i maniakal'no-bredovykh sostoyanii: ot dokazatel'nykh nauchnykh issledovanii k klinicheskim rek-omendatsiyam // Biologicheskie metody terapii psikhicheskikh rasstroistv. Dokazatel'naya med-itsina – klinicheskoi praktike / pod red. S.N. Mosolova. – M., 2012. – S. 554–585.
  • 9. Ushkalova A.V. Diagnostika i podkhody k farmakoterapii depressivnoi fazy bipoly-arnogo affektivnogo rasstroistva II tipa: dis. … kand. med. nauk. – M., 2014.
  • 10. Coryell W., Solomon D., Turvey C. et al. The long-term course of rapid-cycling bipolar disorder // Arch Gen Psychiatry. – 2003. –Vol. 60, No. 9. – P. 914–920.
  • 11. Suppes T., Kelly D., Perla J.M. Challenges in the management of bipolar depression // J Clin Psychiatry. – 2005. – Vol. 66, Suppl. 5. – P. 11–16.
  • 12. Mosolov S.N., Kostyukova E.G. i dr. Profilakticheskaya effektivnost' val'proata natriya, lamotridzhina i topiramata u bol'nykh s bipolyarnym affektivnym rasstroistvom s chastymi retsidivami (prospektivnoe, otkrytoe, sravnitel'noe issledovanie) // Biologicheskie metody terapii psikhicheskikh rasstroistv. Dokazatel'naya meditsina – klinicheskoĭ praktike / pod red. S.N. Mosolova. – M., 2012. – S. 586–622.
  • 13. Ghaemi S.N., Hsu D.J., Soldani F., Goodwin F.K. Antidepressants in bipolar disorder: the case for caution // Bipolar Disord. – 2003. – Vol. 5, No. 6. – P. 421–433.
  • 14. Merikangas K.R., Jin R., He J.P. et al. Prevalence and correlates of bipolar spectrum dis-order in the world mental health survey initiative // Arch Gen Psychiatry. – 2011. – Vol. 68, No. 3. – P. 241–251.
  • 15. Weisenbach S.L., Marshall D., Weldon A.L. et al. The double burden of age and disease on cognition and quality of life in bipolar disorder // Int J Geriatr Psychiatry. – 2014. – Vol. 29, No. 9. – P. 952–961.
  • 16. Judd L.L., Akiskal H.S., Schettler P.J. et al. Psychosocial disability in the course of bipo-lar II disorders and I: a prospective, comparative, longitudinal study // Arch Gen Psychiatry. – 2005. – Vol. 62. – P. 1322–1330.
  • 17. Chen L., Liu Y.H., Zheng Q. et al. Suicide risk in major affective disorder. Results from a national survey in China // J Affect Disord. – 2014. – Vol. 155. – P. 174–179.
  • 18. Kostyukova E.G. Vozmozhnosti individualizirovannogo podkhoda k normotimicheskoi terapii bipolyarnogo affektivnogo rasstroistva // Sovremennaya terapiya psikhicheskikh ras-stroistv. – 2015. – № 4. – S. 15–23.
  • 19. Kostyukova E.G., Mosolov S.N. Sovremennye podkhody k diagnostike, lecheniyu i pro-filaktike depressii pri bipolyarnom rasstroistve. // Sotsial'naya i klinicheskaya psikhiatriya. – 2003. – № 4. – C. 106–114.
  • 20. Kostyukova E.G., Mosolov S.N. Soli litiya i antikonvul'santy pri profilaktike retsidivov bipolyarnogo affektivnogo rasstroistva // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2012. – № 4. – S. 2–10.
  • 21. Mosolov S.N., Ushkalova A.V., Kostyukova E.G. s soavt. Diagnostika bipolyarnogo af-fektivnogo rasstroistva II tipa sredi patsientov s tekushchim diagnozom rekurrentnogo depres-sivnogo rasstroistva // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2014. – Vyp. 2. – S. 2–14.
  • 22. Mosolov S., Ushkalova A., Kostukova E. et al. Bipolar II disorder in patients with a cur-rent diagnosis of recurrent depression // Bipolar Disord. – 2014. – Vol. 16. – P. 389–399.
  • 23. Mosolov S.N., Shafarenko A.A., Ushkalova A.V. s soavt. Formalizovannaya diagnostika bipolyarnogo affektivnogo rasstroistva u bol'nykh s pristupoobraznoi shizofreniei i shizoaffek-tivnym rasstroistvom // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2014. – Vyp. 3. – S. 2–8.
  • 24. Mosolov S.N., Kostyukova E.G., Ushkalova A.V. Problemy diagnostiki i terapii bipoly-arnoi depressii: ot dokazatel'nykh nauchnykh issledovanii k klinicheskim rekomendatsiyam // Biologicheskie metody terapii psikhicheskikh rasstroistv Mosolov S.N. dokazatel'naya meditsina – klinicheskoĭ praktike / pod red. S.N. Mosolova. – M., 2012. – S. 529–553.
  • 25. Vieta E, Blasco-Colmenares E, Figueira ML, et al. Clinical management and burden of bipolar disorder: a multinational longitudinal study (WAVE-bd study) // BMC Psychiatry. – 2011. – Vol. 11. – P. 11–58.
  • 26. Mosolov S.N., Kostyukova E.G., Ushkalova A.V. s soavt. Algoritmy biologicheskoi ter-apii bipolyarnogo affektivnogo rasstroistva // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2013. – № 4. – S. 31–39.
  • 27. Mosolov S.N., Kostyukova E.G., Tsukarzi E.E. Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniyu bipolyarnogo affektivnogo rasstroistva u vzroslykh (proekt) // Rossi-iskoe obshchestvo psikhiatrov. 25.11.13. – URL: http://psychiatr.ru/news/183
  • 28. Goodwin G.M., Haddad P.M., Ferrier et al. Evidence-based guidelines for treating bipo-lar disorder: revised third edition Recommendations from the British Association for Psycho-pharmacology // J Psychopharmacol. – 2016. – Vol. 30, No. 6. – P. 495–553.
  • 29. Grunze H., Vieta E., Goodwin G.M. et al. The World Federation of Societies of Biologi-cal Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long term treatment of bipolar disorder // World J Biol Psychiatry. – 2013. – Vol. 14. – P. 154–219.
  • 30. Vieta E., Murru A., Pueyo M.J. Guia sobre el maneig del tratorn bipolar a Catalunya. – Barcelona: Agencia d’Informacio, Avaluacio i Qualitat en Salut. Servei Catala` de la Salut. De-partament de Salut. Generalitat de Catalunya, 2011.
  • 31. Yatham L.N., Kennedy S.H., Parikh S.V. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013 // Bipolar Disord. – 2013. – Vol. 15, No 1. – P. 1–44.
  • 32. Kostyukova E.G., Shafarenko A.A., Ladyzhenskii M.Ya. Problemy i novye vozmozhnosti differentsirovannoi terapii bol'nykh bipolyarnym rasstroistvom// Sovremennaya terapiya psikhicheskikh rasstroistv. – 2014. – № 4. – S. 8–14.
  • 33. Fedotov D.D., Kostyukova E.G., Mosolov S.N. Differentsiirovannyi prognoz effek-tivnosti profilakticheskoi terapii lamotridzhinom, val'proatom i topiramatom u bol'nykh s chastymi retsidivami bipolyarnogo affektivnogo rasstroistva pervogo i vtorogo tipov // Sotsi-al'naya i klinicheskaya psikhiatriya. – 2014. – T. 24, № 3. – S. 77–83.
  • 34. Shafarenko A.A., Kapiletti S.G., Mosolov S.N. Sravnitel'naya effektivnost' i perenosi-most' atipichnykh antipsikhotikov pri kupirovanii maniakal'nykh sostoyanii v ramkakh shizoaffektivnogo i bipolyarnogo rasstroistv // Sotsial'naya i klinicheskaya psikhiatriya. – 2011. – T. 21, № 3. – S. 58–65.
  • 35. Cipriani A., Barbui C., Salanti G. et al. Comparative efficacy and acceptability of anti-manic drugs in acute mania: a multiple-treatments meta-analysis // Lancet. – 2011. – Vol. 378. – P. 1306–1315.
  • 36. Okuma T. A history of investigation on the mood-stabilizing effect of carbamazepine in Japan // Seishin Shinkeigaku Zasshi. – 2002. –Vol. 104, No. 8. – P. 647–655.
  • 37. Ballenger J.C., Post R.M. Carbamazepine in manic depressive illness: a new treatment // Am J Psychiatry. –1980. – Vol. 137. –P. 782–790.
  • 38. Weisler R.H., Hirschfeld R., Cutler A.J. et al. SPD417 Study Group. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two random-ised, double-blind, placebo-controlled trials // CNS Drugs. – 2006. – Vol. 20, No. 3. – P. 219–231.
  • 39. Weisler R.H., Kalali A.H., Ketter T.A. SPD417 Study Group. A multicenter, random-ized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as mon-otherapy for bipolar disorder patients with manic or mixed episodes // J Clin Psychiatry. – 2004. – Vol. 65, No. 4. – P. 478–484.
  • 40. Yildiz A., Nikodem M., Vieta E., Correll C.U., Baldessarini R.J. A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania // Psychol Med. – 2015. – Vol. 45, No. 2. – P. 299–317.
  • 41. Macritchie K., Geddes J.R., Scott J. et al. Valproate for acute mood episodes in bipolar disorder // Cochrane Database Syst Rev. – 2003. – No. 1. – CD004052.
  • 42. El-Mallakh R.S., Ketter T.A., Weisler R.H. et al. Switching from other agents to extend-ed-release carbamazepine in acute mania // Psychopharmacol Bull. – 2008. – Vol. 41, No. 1. – P. 52–58.
  • 43. El-Mallakh R.S., Salem M.R., Chopra A.S. et. Adverse event load in bipolar participants receiving either carbamazepine immediate-release or extended-release capsules: a blinded, ran-domized study // Int Clin Psychopharmacol. – 2009. – Vol. 24, No. 3. – P. 145–149.
  • 44. Pope H.G. Jr., McElroy S.L., Keck P.E. Jr., Hudson J.I. Valproate in the treatment of acute mania. A placebo-controlled study // Arch Gen Psychiatry. – 1991. – Vol.48, No. 1. – P. 62–68.
  • 45. Bowden C.L., Brugger A.M., Swann A.C. et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group // JAMA. – 1994. – Vol. 30, No. 12. – P. 918–924.
  • 46. Bowden C.L., Mosolov S., Hranov L. et al. Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial // International Clinical Psychopharmacology. – 2010. – Vol. 25, No. 2. – P. 60–67.
  • 47. Yildiz A., Vieta E., Leucht S. et al. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials // Neuropsychopharmacology. – 2011. – Vol. 36, No. 2. – P. 375–389.
  • 48. Allen M.H., Hirschfeld R.M., Wozniak P.J. et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania // Am J Psychiatry. – 2006. – Vol. 163, No. 2. – P. 272–275.
  • 49. Bowden C.L., Singh V. Lamotrigine (Lamictal IR) for the treatment of bipolar disorder. // Expert Opin Pharmacother. – 2012. – Vol. 13, No. 17. – P. 2565–2571.
  • 50. Rosa A.R., Fountoulakis K., Siamouli M., Gonda X., Vieta E. Is anticonvulsant treat-ment of mania a class effect? Data from randomized clinical trials // CNS Neurosci Ther. – 2011. – Vol. 17, No 3. – P. 167–177.
  • 51. Malhi G.S., Adams D., Berk M. Medicating mood with maintenance in mind: bipolar depression pharmacotherapy // Bipolar Disord. – 2009. – Vol. 11, Suppl. 2. – P. 55–76.
  • 52. Ushkalova A., Ushkalova E. Farmakoterapiya bipolyarnogo affektivnogo rasstroistva vo vremya beremennosti i v poslerodovom periode // Vrach. – 2012. – № 8. – S. 15–19.
  • 53. Ushkalova A.V., Kostyukova E.G., Mosolov S.N. Varianty farmakoterapii depressivnoi fazy bipolyarnogo affektivnogo rasstroistva // Zhurnal nevrologii i psikhiatrii im. C.C. Korsa-kova. – 2015. – T. 115, № 1–2. – S. 23–30.
  • 54. Ushkalova A.V., Kostyukova E.G., Mosolov S.N. Sovremennaya terapiya depressivnoi fazy pri bipolyarnom affektivnom rasstroistve // Zhurnal nevrologii i psikhiatrii im. C.C. Korsa-kova. – 2012. – T. 112, № 11–2. – S. 67–76.
  • 55. Kasper S., Calabrese J.R., Johnson G. et al. International Consensus Group on the Evi-dence-based Pharmacological Treatment of Bipolar I and II Depression // J Clin Psychiatry. – 2008. – Vol. 69, No. 10. – P. 1632–1646.
  • 56. NICE Clinical Guidelines. Bipolar disorder. The management of bipolar disorder in Padults, children and adolescents, in primary and secondary care. – National Institute for Health and Clinical Excellence, 2009.
  • 57. Popovic D., Reinares M., Goikolea J.M. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder // Eur Neuropsychopharmacol. – 2012. – Vol. 22, No. 5. – P. 339–346.
  • 58. Smith L.A., Cornelius V.R., Azorin J.M. et al. Valproate for the treatment of acute bipo-lar depression: systematic review and meta-analysis // J Affect Disord. – 2010. – Vol. 122 (1–2). – P. 1–9.
  • 59. Calabrese J.R., Bowden C.L., McElroy S.L. et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder // Am J Psychiatry. – 1999. – Vol. 156. – P. 1019–1023.
  • 60. Geddes J.R., Calabrese J.R., Goodwin G.M. Lamotrigine for treatment of bipolar depres-sion: independent meta-analysis and meta-regression of individual patient data from five ran-domised trials // Br J Psychiatry. – 2009. – Vol. 194. – P. 4– 9.
  • 61. Srivastava S., Ketter T.A. Clinical relevance of treatments for acute bipolar disorder: balancing therapeutic and adverse effects // Clin Ther. – 2011. – Vol. 33, No. 12. – P. 40–84.
  • 62. Vázquez G.H., Holtzman J.N. et al. Efficacy and tolerability of treatments for bipolar depression // J Affect Disord. – 2015. – Vol. 183. – P. 258–262.
  • 63. Reinares M., Rosa A.R., Franco C. et al. A systematic review on the role of anticonvul-sants in the treatment of acute bipolar depression // Int J Neuropsychopharmacol. –2013. – Vol. 16, No. 2. – P. 485– 496.
  • 64. Vieta E., Locklear J., Günther O. et al. Treatment options for bipolar depression: a sys-tematic review of randomized, controlled trials // J Clin Psychopharmacol. – 2010. – Vol. 30. – P. 579–590.
  • 65. Fountoulakis K.N., Kasper S., Andreassen O. et al. Efficacy of pharmacotherapy in bipo-lar disorder: a report by the WPA section on pharmacopsychiatry // Eur Arch Psychiatry Clin Neurosci. – 2012. – Vol. 262, No. 1. – P. 1–48.
  • 66. Azorin J.M., Belzeaux R., Cermolacce M. et al. Recommendations for the treatment of mixed episodes in current guidelines // Encephale. – 2013. – Vol. 39, No. 3. – P. 185–187.
  • 67. McIntyre R.S., Yoon J. Efficacy of antimanic treatments in mixed states // Bipolar Dis-ord. – 2012. – Suppl. 2. – P. 22–36.
  • 68. Swann A.C., Bowden C.L., Morris D. et al. Depression during mania. Treatment re-sponse to lithium or divalproex // Arch Gen Psychiatry. – 1997. – Vol. 54, No. 1. – P. 37–42.
  • 69. Woo Y.S., Lee J.G., Jeong J.H. et al. Korean Medication Algorithm Project for Bipolar Disorder: third revision // Neuropsychiatr Dis Treat. – 2015. – Vol. 11. – P. 493–506.
  • 70. Goodwin F.K., Jamison K. Manic-depressive illness // Bipolar disorders and recurrent depression. 2nd ed. – Cambridge: Oxford Press, 2007.
  • 71. Geddes J.R., Miklowitz D.J. Treatment of bipolar disorder // Lancet. – 2013. – Vol. 381. – P. 1672–1682.
  • 72. Vieta E., Valentí M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis // CNS Drugs. – 2013. – Vol. 27, No. 7. – P. 515–529.
  • 73. Okuma T., Inanaga K., Otsuki S. et al. A preliminary double blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology. – 1981. –Vol. 73, No. 1. – P. 95–96.
  • 74. Chen C.H., Lin S.K. Carbamazepine treatment of bipolar disorder: a retrospective evalu-ation of naturalistic long-term outcomes // BMC Psychiatry. – 2012. – Vol. 12. – P. 47.
  • 75. Akiskal H.S., Fuller M.A., Hirschfeld R.M. et al. Reassessing carbamazepine in the treatment of bipolar disorder: clinical implications of new data // CNS Spectr. – 2005. – Vol. 10, No. 6. – P. l–11.
  • 76. Bowden C.L. Anticonvulsants in bipolar disorders: current research and practice and fu-ture directions // Bipolar Disord. – 2009. –Vol. 11, No. 2. – P. 20–33.
  • 77. Dardennes R., Even C., Bange F., Heim A. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders. A meta-analysis // Br J Psychiatry. – 1995. – Vol. 166, No. 3. – P. 378–381.
  • 78. Ketter T.A., Kalali A.H., Weisler R.H. SPD417 Study Group. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipo-lar disorder patients with manic or mixed episode // Clin Psychiatry. – 2004. – Vol.65, No 5. – P. 668–673.
  • 79. Vieta E., Gunther O., Locklear J. et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials // Int J Neuropsychopharmacol. – 2011. – Vol.14, No. 8. – P. 1029–1049.
  • 80. Bowden C.L., Calabrese J.R., McElroy S.L. et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Di-valproex Maintenance Study Group // Arch Gen Psychiatry. – 2000. – Vol. 57, No. 5. – P. 481–489.
  • 81. Geddes J.R., Goodwin G.M., Rendell J. et al. Lithium plus valproate combination thera-py versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial // Lancet. –2010. – Vol. 375. – P. 385–395.
  • 82. Beynon S., Soares-Weiser K., Woolacott N. et al. Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials // J Psycho-pharmacol. – 2009. – Vol. 23. – P. 574–591.
  • 83. Oquendo M.A., Galfalvy H.C., Currier D. et al. Treatment of suicide attempters with bi-polar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior // Am J Psychiatry. – 2011. – Vol. 168. – P. 1050–1056.
  • 84. Mosolov S.N. Sravnitel'naya effektivnost' profilakticheskogo primeneniya karbonata liti-ya, karbamazepina i val'proata natriya pri affektivnykh i shizoaffektivnykh psikhozakh // Zhurn. nevropatol. i psikhiatr. im. S.S. Korsakova. – 1991. – № 4. – S. 78–83.
  • 85. Kuzavkova M.V. Kliniko-farmakokineticheskii prognoz effektivnosti normotimikov pri vtorichnoi profilaktike faznoprotekayushchikh endogennykh psikhozov: diss. … kand. med. nauk. – M., 2001.
  • 86. Cipriani A., Reid K., Young A.H. et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder // Cochrane Database Syst Rev. – 2013. – No. 10. – CD003196.
  • 87. Bowden C.L., Calabrese J.R., Sachs G. et al. Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder // Arch Gen Psychiatry. – 2003. –Vol. 60, No. – P. 392–400.
  • 88. Calabrese J.R., Bowden C.L., Sachs G. et al. Lamictal 605 Study Group. A placebo con-trolled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder // J Clin Psychiatry. – 2003. –Vol. 64, No. 9. – P. 1013–1024.
  • 89. Goodwin G.M., Bowden C.L., Calabrese J.R. et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder // J Clin Psychiatry. – 2004. – Vol. 65. – P. 432–441.
  • 90. Jung I., Lee M., Kang B. et al. Lamotrigine treatment for patients with bipolar II disor-der: retrospective report of 30 cases // Bipolar Disord. – 2008. – Vol. 10, No. 1. – P. 45–46.
  • 91. Sharma V., Khan M., Corpse C. Role of lamotrigine in the management of treatment-resistant bipolar II depression: a chart review // J Affect Disord. – 2008. – Vol. 111, No. 1. – P. 100–105.
  • 92. Goldsmith D.R., Wagstaff A.J., Ibbotson T., Perry C.M. Spotlight on lamotrigine in bi-polar disorder // CNS Drugs. – 2004. – Vol. 18, No. 1. – P. 63–67.
  • 93. Seo H.J., Chiesa A., Lee S.J. et al. Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications // Clin Neuropharmacol. – 2011. – P. 34, No. 1. – P. 39–47.
  • 94. Coryell W. Rapid cycling bipolar disorder: clinical characteristics and treatment options. // CNS Drugs. – 2005. – Vol. 19, No. 7. – P. 557–569.
  • 95. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision) // Am J Psychiatry. – 2002. – Vol. 159, No 4. – P. 1–50.
  • 96. Fountoulakis K.N., Kontis D., Gonda X. et al. A systematic review of the evidence on the treatment of rapid cycling bipolar disorder // Bipolar Disord. – 2013. – Vol. 15, No. 2. – P. 115–137.
  • 97. Vieta E., Valenti M. Mixed states in DSM-5: implications for clinical care, education, and research // J Affect Disord. – 2013. – Vol. 148, No. 1. – P. 28–36.
  • 98. Goldberg J.F., Freeman M.P., Balon R. et al. The American society of clinical pharma-cology survey of psychopharmacologists' practice patterns for the treatment of mood disorders // Depress Anxiety. – 2015. – Vol. 32, No 8. – P. 605–613.
  • 99. Denicoff K.D., Smith-Jackson E.E., Disney E.R. et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder // J Clin Psychiatry. – 1997. –Vol. 58, No. 11. – P. 470–478.
  • 100. Calabrese J.R., Suppes T., Bowden C.L. et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group // J Clin Psychiatry. – 2000. – Vol. 61, No. 11. – P. 841–850.
  • 101. Calabrese J.R., Shelton M.D., Rapport D.J. et al. Bipolar disorders and the effectiveness of novel anticonvulsants // J Clin Psychiatry. – 2002. – Vol. 63, No. 3. – P. 5–9.
  • 102. Goldberg J.F., Bowden C.L., Calabrese J.R. et al. Six-month prospective life charting of mood symptoms with lamotrigine monotherapy versus placebo in rapid cycling bipolar disorder // Biol Psychiatry. – 2008. – Vol. 63, No. 1. – P. 125–130.
  • 103. Calabrese J.R., Vieta E., Shelton M.D. Latest maintenance data on lamotrigine in bipolar disorder // Eur Neuropsychopharmacol. – 2003. – Vol. 2. – P. 57–66.
  • 104. Frye M.A., Ketter T.A., Kimbrell T.A. et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders // J Clin Psychopharmacol. – 2000. – Vol. 20, No. 6. – P. 607–614.
  • 105. Grunze H., Walden J. Katayama et al. Therapeutic window of lamotrigine for mood dis-orders: a naturalistic retrospective study // Pharmacopsychiatry. – 2014. – Vol. 47. – P. 111–114.
  • 106. Katayama Y., Terao T., Kamei K., Hatano K. et al. Therapeutic window of lamotrigine for mood disorders: a naturalistic retrospective study // Pharmacopsychiatry. – 2014. – Vol. 47, No. 3. – P. 111–114.
  • 107. Goldberg J.F., Calabrese J.F., Saville B.R. et al. Mood stabilization and destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo // J Clin Psychiatry. – 2009. –Vol. 79, No. 9. – P. 1273–1280.
  • 108. National Collaborating Centre for Mental Health. Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. – London (UK): National Institute for Health and Care Excellence (NICE); 2014. Sep. – 58 p. (Clinical guideline; No. 185).
  • 109. Price A.L., Marzani-Nissen G.R. Bipolar disorders: a review // Am Fam Physician. – 2012. – Vol. 85, No. 5. – P. 483–493.
  • 110. Ushkalova A.V., Ushkalova E.A. Vliyanie protivosudorozhnykh preparatov na kogni-tivnye i povedencheskie funktsii // Farmateka – 2009. – № 7. – S. 13–18.
  • 111. Murru A., Popovic D., Pacchiarotti I. et al. Management of adverse effects of mood sta-bilizers // Curr Psychiatry Rep. – 2015. – Vol. 17, No. 8. – P. 603.
  • 112. Verrotti A. et al. Antiepileptic drugs, sex hormones, and PCOS // Epilepsia. – 2011 –Vol. 52, No. 2. – P. 199–211.
  • 113. Ushkalova A.V., Ushkalova E.A. Primenenie normotimicheskikh sredstv vo vremya beremennosti // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2012. – № 3. – S. 9–15.
  • 114. Diav-Citrin O., Shechtman S. et al. Is carbamazepine teratogenic? A prospective con-trolled study of 210 pregnancies // Neurology. – 2001. – Vol. 57. – P. 321–324.
  • 115. Meador K., Reynolds M.W., Crean S. et al. Pregnancy outcomes in women with epilep-sy: a systematic review and meta-analysis of published pregnancy registries and cohorts // Epi-lepsy Res. – 2008. – Vol. 81, No. 1. – P. 1–13.
  • 116. Ward S., Wisner L. Collaborative Management of Women with Bipolar Disorder During Pregnancy and Postpartum: Pharmacologic Considerations // J Midwifery Womens Health. –2007.–Vol.52, No. 1. – P. 3–13.
  • 117. Holmes L.B., Wyszynski D.F., Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience // Arch Neurol. – 2004. – Vol. 65, No. 5. – P. 673–678.
  • 118. Karceski S., Morrell M., Carpenter D: The expert consensus guideline series: treatment of epilepsy // Epilepsy Behav. – 2001. – Vol. 2. – P. 1–50.
  • 119. Hiilesmaa V.K., Teramo K., Granstrom M.L. et al. Fetal head growth retardation associ-ated with maternal antiepileptic drugs // Lancet. – 1981. – Vol. 2. – P. 165–167.
  • 120. Costoloni G., Pierantozzi E., Goracci A. et al. Mood stabilisers and pregnancy outcomes – a review // Psychiatr Pol. – 2014. – Vol. 48, No. 5. – P. 865–887.
  • 121. Samren E.B., van Duijn C.M., Christiaens G.C. et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring // Ann Neurol. – 1999. – Vol. 46, No. 5. – P. 739–746.
  • 122. Scolnick D. Neurodevelopment of children exposed in utero to phenytoin and carbamaz-epine monotherapy // JAMA. – 1994. – Vol. 271. – P. 767–770.
  • 123. Bowden C.L. Valproate // Bipolar Disord. – 2003. – Vol. 5, No. 3. – P. 189–202.
  • 124. Morrow J., Russell A., Guthrie E. et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register // J Neurol Neu-rosurg Psychiatry. – 2006. – Vol. 77, No. 2. – P. 193–198.
  • 125. Tohen M., Ketter T.A., Zarate C.A. et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study // Am J Psychiatry. – 2003. – Vol. 160, No. 7. – P. 1263–1271.
  • 126. Gerstner T. et al. Valproate-associated coagulopathies are frequent and variable in chil-dren // Epilepsia. – 2006. –Vol. 47, No. 7. – P. 1136–1143.
  • 127. Kennedy D., Koren G. Valproic acid use in psychiatry: issues in treating women of re-productive age // J Psychiatry Neuroscience. – 1998. – Vol. 23. – P. 223–228.
  • 128. Meador K.J., Penovich P., Baker G.A. et al. Antiepileptic drug use in women of childbearing age // Epilepsy Behav. – 2009. –Vol. 15, No. 3. – R. 339–343.
  • 129. Minagawa K., Watanabe T., Oyanagi R. Characteristics of women with epilepsy who developed polycystic ovary syndrome owing to the therapy with valproate sodium // No To Hattatsu. – 2013. – Vol. 45, No. 4. – P. 304–308.
  • 130. Gentile S. Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions // CNS Spectr. – 2014. –Vol. 26, No. 1. – P. 11.
  • 131. Wang X.Q., Xiong J., Xu W.H. et al. Risk of a lamotrigine-related skin rash: current me-ta-analysis and postmarketing cohort analysis // Seizure. – 2015. – Vol. 25. – P. 52–61.
  • 132. Bowden C.L., Calabrese JR, Ketter TA et al. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder // Am J Psychiatry. – 2006. – Vol. 163, No. 7. – P. 1199–1201.
  • 133. Chuang Y.C. et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis // Epilepsia. – 2012. – Vol. 53, No. 1. – P. 120–128.
  • 134. Sachs G., Bowden C., Calabrese J.R. et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder // Bipolar Disord. – 2006. – Vol. 82. – P. 175–181.
  • 135. Daban C. et al. Cognitive functioning in bipolar patients receiving lamotrigine: prelimi-nary results // J Clin Psychopharmacol. – 2006. – Vol. 26, No. 2. – P. 178–181.
  • 136. Gil-Nagel A. et al. Effect of lamotrigine on sexual function in patients with epilepsy // Seizure. – 2006. – Vol. 15, No. 3. – P. 142–149.
  • 137. Cunnington M., Ferber S., Quartey G. International Lamotrigine Pregnancy Registry Scientific Advisory C. Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study // Epilepsia. – 2007. – Vol. 48, No. 6. – P. 1207–1210.
  • 138. Hunt S.J., Craig J.J., Morrow J.I. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy // Neurology. –2009. – Vol. 72, No. 12. – P. 1108.
  • 139. Mølgaard-Nielsen D., Hviid A. Newer-generation antiepileptic drugs and the risk of ma-jor birth defects // JAMA. – 2011. – Vol. 305, No. 19. – P. 1996–2002.